| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Purchases of marketable debt securities | NaN | 0 | NaN | 0 |
| Proceeds from sales of marketable debt securities | NaN | 0 | NaN | 0 |
| Proceeds from sale of assets | NaN | 15 | 320 | NaN |
| Net cash provided by (used in) investing activities | 0 | 15 | 320 | 0 |
| Net proceeds from public offerings of common stock and warrants | NaN | 0 | NaN | 0 |
| Gross proceeds from private placement of preferred stock and common stock warrants | 0 | 0 | 0 | 3,300 |
| Amortization of bond premium | NaN | 0 | NaN | 0 |
| Transaction costs paid pursuant to private placement | 0 | 0 | 0 | 29 |
| Impairment charges of goodwill and other intangible assets | NaN | 0 | NaN | NaN |
| Net proceeds from exercise of warrants | NaN | 65 | 64 | NaN |
| Impairment charges of other assets | NaN | 0 | NaN | NaN |
| Payments of finance lease liability principal | 0 | 7 | 0 | 2 |
| Income tax benefit | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | 0 | 58 | 64 | 3,269 |
| Depreciation and amortization | 0 | 3 | -1 | 30 |
| Gain on sale of assets | NaN | NaN | 0 | 110 |
| Change in fair value of warrant liability | 0 | 0 | 0 | 3,161 |
| Net gain on disposal of assets | NaN | 37 | NaN | NaN |
| Amortization of finance lease right-of-use assets | 0 | 1 | 1 | 2 |
| Loss on operating lease right-of-use assets modification | NaN | 241 | NaN | NaN |
| Operating lease liabilities | -165 | -484 | -195 | -363 |
| Prepaid expenses and other current assets | 341 | -141 | -205 | -319 |
| Accounts payable | 397 | 235 | -86 | 71 |
| Accrued expenses and other liabilities | 242 | -115 | -230 | -1,008 |
| Net loss | -1,921 | -1,912 | -1,532 | -6,901 |
| Amortization of operating lease right-of-use assets | 74 | 91 | 111 | 218 |
| Stock based compensation expense | 113 | 217 | 253 | 553 |
| Net cash used in operating activities | -1,601 | -1,509 | -1,474 | -4,028 |
| Net decrease in cash, cash equivalents and restricted cash | -1,601 | -1,436 | NaN | NaN |
| Net decrease in cash, cash equivalents and restricted cash | -1,601 | -1,436 | -1,090 | -759 |
| Cash, cash equivalents and restricted cash at beginning of period | 4,249 | 5,685 | 7,534 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 2,648 | 4,249 | 5,685 | NaN |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)